Aug 12, 2025 4:15pm EDT DiaMedica Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Aug 05, 2025 4:15pm EDT DiaMedica Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update August 13, 2025
Jul 21, 2025 8:00am EDT DiaMedica Therapeutics Raises $30 Million in Private Placement to Accelerate Industry Leading Preeclampsia and Fetal Growth Restriction Pipeline
Jul 17, 2025 8:00am EDT DiaMedica Therapeutics Reports Positive Interim Phase 2 Preeclampsia Results: Statistically Significant Reductions in Blood Pressure and No Placental Transfer
Jun 24, 2025 8:30am EDT DiaMedica Therapeutics Announces Inclusion in the Russell 2000® and Russell 3000® Indexes
May 22, 2025 8:30am EDT DiaMedica Therapeutics to Present at Jefferies Global Healthcare Conference 2025
May 19, 2025 9:00am EDT DiaMedica Therapeutics Announces Key Opinion Leader Webinar on DM199 (Rinvecalinase Alfa) for the Treatment of Preeclampsia
May 14, 2025 4:30pm EDT DiaMedica Therapeutics Announces Poster Presentation at European Stroke Organisation Conference – ESOC 2025
